DrugDashboards

Estradiol valerate

Estradiol valerate · ESTRADIOL VALERATE 40 mg/mL · Injection · Intramuscular · Xiromed, LLC

NDC 70700-0275-22 · 5 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The generic price has held steady around $35.06 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$35.06per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$7.70per billing unit (10 MG)HCPCS J1380 · Jul 1, 2026
  • Part D plans paid (avg)$22.32per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$148.46per package of 5MLAvKare, LLC · Aug 7, 2023

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$20.00$40.00Jul 2023Sep 2026$35.06
37 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$217.22
Reported to Texas DSHS · 2026 annual filing · Xiromed, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$7.702
HCPCS J1380 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$1.5M
10,690 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for estradiol valerate (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $129.86 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA216656
TE code
AO
Approval date
Apr 28, 2023
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Estradiol valerate (Injection)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.ESTRADIOL VALERATE 20 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.ESTRADIOL VALERATE 10 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.ESTRADIOL VALERATE 40 mg/mLJul 15, 2026Sep 2, 2026
Par Health USA, LLCESTRADIOL VALERATE 20 mg/mLJul 15, 2026Sep 2, 2026
Par Health USA, LLCESTRADIOL VALERATE 10 mg/mLJul 15, 2026Sep 2, 2026
Xiromed, LLCESTRADIOL VALERATE 20 mg/mLJul 15, 2026Sep 2, 2026
Xiromed, LLCESTRADIOL VALERATE 10 mg/mLJul 15, 2026Sep 2, 2026
Xiromed, LLCESTRADIOL VALERATE 40 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Estradiol valerate — NDC 70700-0275-22," retrieved September 3, 2026, https://drugdashboards.com/drug/70700027522.

Free to cite with attribution — see how the data is put together.